Table 5.
Anti-depressants and isoform mRNA expression5
Drug | Region | Direction | Isoform | Publication |
---|---|---|---|---|
Tranylcypromine (10 mg/kg) | Hippocampus | Increased | B1a, B2 | Sands et al., 2003 |
Phenelzine (10 mg/kg) | Hippocampus | Increased | B1a | |
Fluoxetine (5 mg/kg) | Hippocampus | Increased | B1a | |
Fluoxetine (5 mg/kg) | Lumbar spinal cord | Increased; Decreased | B1a; B2 | McCarson et al., 2006 |
Desipramine (15 mg/kg) | Hippocampus | Increased | B1a | Sands et al., 2003 |
Desipramine (15 mg/kg) | Spinal cord dorsal horn | Increased | B1a, B2 | Sands et al., 2004 |
Amitriptyline (10 mg/kg) | Lumbar spinal cord | Increased; Decreased | B1a, B1b; B2 | McCarson et al., 2006 |
Table 5 indicates the effects of different antidepressants on GABABR subunit and isoform expression. All results were gathered using in situ hybridization, and direction indicates a comparison to baseline. Tranylcypromine and phenelzine are MAOIs, fluoxetine is an SSRI, and desipramine and amitriptyline are tricyclics.